GSK’s (GSK) “Buy” Rating Reaffirmed at Berenberg Bank

GSK (LON:GSK)‘s stock had its “buy” rating reiterated by Berenberg Bank in a note issued to investors on Wednesday, Digital Look reports. They currently have a GBX 1,820 ($23.24) price objective on the stock. Berenberg Bank’s price target would suggest a potential upside of 14.16% from the stock’s current price.

Other research analysts have also recently issued reports about the stock. Deutsche Bank Aktiengesellschaft dropped their price objective on shares of GSK from GBX 1,950 ($24.90) to GBX 1,850 ($23.62) and set a “buy” rating for the company in a research note on Wednesday, July 31st. Citigroup lowered their target price on shares of GSK from GBX 2,120 ($27.07) to GBX 1,900 ($24.26) and set a “buy” rating for the company in a research note on Friday, July 5th. Jefferies Financial Group reissued a “buy” rating and set a GBX 2,100 ($26.81) price objective on shares of GSK in a research note on Thursday, June 27th. JPMorgan Chase & Co. reissued an “underweight” rating on shares of GSK in a research note on Monday, July 29th. Finally, Shore Capital reissued a “buy” rating on shares of GSK in a research note on Thursday, June 27th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of GBX 1,805.71 ($23.06).

GSK Price Performance

GSK stock opened at GBX 1,594.28 ($20.36) on Wednesday. The company has a current ratio of 0.82, a quick ratio of 0.73 and a debt-to-equity ratio of 123.04. The firm has a 50 day moving average of GBX 1,554.42 and a 200-day moving average of GBX 1,636.22. GSK has a 12-month low of GBX 1,340 ($17.11) and a 12-month high of GBX 1,823.50 ($23.28). The company has a market cap of £65.05 billion, a price-to-earnings ratio of 1,411.50, a PEG ratio of 1.45 and a beta of 0.29.

Insiders Place Their Bets

In other news, insider Wendy Becker bought 446 shares of the firm’s stock in a transaction on Thursday, June 20th. The stock was purchased at an average price of GBX 1,614 ($20.61) per share, for a total transaction of £7,198.44 ($9,191.06). In the last 90 days, insiders bought 462 shares of company stock worth $744,868. Insiders own 1.61% of the company’s stock.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.